Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
Inspira Technologies announced on February 9, 2026, that it has secured vendor approval from Clalit Health Services, the world’s second-largest integrated HMO with about 4.9 million members, enabling immediate procurement and deployment of its INSPIRA ART100 system across Clalit’s hospitals and clinics. The decision, following a rigorous technical and clinical review by Clalit’s Professional Committee for Medical Equipment in thoracic and cardiac surgery, marks a significant commercial inflection point that validates the ART100’s safety and efficacy, opens access to one of the most advanced healthcare supply chains globally, and is expected to support long-term revenue and bolster Inspira’s positioning as it pursues broader U.S. and international commercialization.
The approval allows all medical centers in the Clalit network, including 14 major hospitals and more than 1,600 clinics, to initiate procurement in line with Clalit’s supply chain protocols. Management views this as confirmation of the ART100’s suitability for cardiopulmonary procedures, providing a powerful reference case that may influence other health systems and strengthen the company’s life-support and diagnostic technology platform in the competitive MedTech landscape.
The most recent analyst rating on (IINN) stock is a Sell with a $0.68 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.
The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies OXY B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is used for cardiopulmonary bypass in the U.S. and ECMO procedures abroad, and serves as the platform for next-generation systems and its HYLA continuous blood-sensor technology, positioning the firm within the life-support and MedTech market.
Average Trading Volume: 161,495
Technical Sentiment Signal: Strong Sell
Current Market Cap: $25.47M
Find detailed analytics on IINN stock on TipRanks’ Stock Analysis page.